Skip to content
Axcess News – Lifestyle
Author:
Transcenta
Transcenta Therapeutics Presents New Data for its Novel LIV1-Targeting ADC TST013 Demonstrating Potent Anti-Tumor Activity in PDX Models of Prostate Cancer and ER Positive /HER2 Negative Breast Cancer
April 23, 2026
TE Connectivity delivers results above guidance with 15% sales growth and over 20% EPS growth in second quarter of fiscal 2026
April 23, 2026
Transcenta Therapeutics Appoints Dr. Christopher Hwang as Head of Global Partnerships for HiCB Platform
March 30, 2026
Transcenta Therapeutics to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
March 5, 2026